BeiGene vs Lexeo Therapeutics
BeiGene vs Lexeo Therapeutics, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: BeiGene is on 64/100 and Lexeo Therapeutics on 61/100.
Where each one leads
BeiGene
- agent readiness: 50/100 against 40/100
- domain rating: 68/100 against 41/100
Lexeo Therapeutics
- funding raised: $495M against $358M
At a glance
| Measure | BeiGene | Lexeo Therapeutics |
|---|---|---|
| What it is | A global oncology company developing and commercializing innovative cancer treatments. | Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases. |
| Category | Biotech, MedTech, HealthTech, Genomics | Biotech, MedTech, HealthTech, Genomics |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2010 | 2020 |
| Headquarters | Cambridge, United States | New York City, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | BeiGene | Lexeo Therapeutics |
|---|---|---|
| Employees | Not published | 91 |
| Open roles | 100 | Not published |
| Total funding | $358M | $495M |
| Latest round | Secondary Offering | Public Offering |
| Valuation | $15B | Not published |
| LinkedIn followers | Not published | 16,654 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | BeiGene | Lexeo Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 61/100 |
| Traction | 40/100 | 60/100 |
| Team | 30/100 | 70/100 |
| Community | Not published | 8/100 |
| Search visibility | 17/100 | 28/100 |
| Quality | 88/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (50/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 68/100 | 41/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | BeiGene | Lexeo Therapeutics |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CDN | Cloudflare | Not detected |
| CMS | WordPress | WordPress |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Jquery |
| Analytics | Not detected | Google Tag Manager |
BeiGene vs Lexeo Therapeutics: common questions
Which is better, BeiGene or Lexeo Therapeutics?
On our 0-100 score BeiGene rates higher (64/100 against 61/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do BeiGene and Lexeo Therapeutics compare on the numbers?
BeiGene leads on agent readiness (50/100 against 40/100), domain rating (68/100 against 41/100). Lexeo Therapeutics leads on funding raised ($495M against $358M).
Read the full BeiGene review and pricing or the Lexeo Therapeutics review and pricing. You can also browse other BeiGene alternatives we track.